Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The canine atopic dermatitis treatment market is set to experience notable growth, with an expected increase from USD ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

Lebrikizumab, not yet approved in the U.S., and Dupixent (dupilumab) were comparably effective in reducing symptoms after 16 ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...

Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

Eczema is a chronic skin condition that shares similarities with autoimmune skin conditions, but it’s not an autoimmune ...

LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a preclinical study of ZL-1503, the ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...